Minor Changes Still Burdensome to Report Under Revised Variations Regulation, European Industry and Competent Authorities Complain
This article was originally published in The Gold Sheet
Executive Summary
Latest EU variations rewrite leaves both industry and regulators with concerns. Minor changes would still be difficult to implement and pre-notification requirements are seen as unworkable. A plan to subject all biologics changes to prior approval draws ire of biotech sector
You may also be interested in...
Implementing Minor Changes is Hard to Do Under Variations Regulation
European generic drug makers say that it is difficult to implement Type IA changes under the variations regulation because of all the paperwork involved in submitting these changes to competent authorities. A 26 percent fee hike in filing variations is also making it more costly and difficult for manufacturers to justify making changes.
EU Works Toward More Flexibility, Greater Accountability for APIs
More flexibility, greater accountability for APIs expected in Europe with new guidelines on the European Union's variations regulation and an anti-counterfeiting legislative proposal, say speakers at APIC/CEFIC meeting in Paris. The European Parliament has agreed with a European Commission proposal to require communitywide alignment of member state variations requirements, and to allow more types of manufacturing changes to proceed without prior approval. However, EU API makers have some concerns. Quality by design for APIs discussed. European Commission proposes counterfeit directive requiring tracking features, audits of API manufacturers and posting of inspection results. Tips shared for auditing API suppliers and traders.
European Commission Proposes to Ease Variations Process for Manufacturing Changes
CHANGE IS IN THE AIR with the European Commission proposing to simplify and further harmonize the EU variations regulation to ease the global manufacturing change process. The commission would impose a community-wide approach that adds easier “do and tell” procedures for minor variations, includes the ICH design space concept and converges with FDA’s evolving supplement filing process, which will also become easier under a guidance that agency is drafting.